-
Something wrong with this record ?
Cdk2 inhibition prolongs G1 phase progression in mouse embryonic stem cells
Zuzana Koledova, Leona Raskova Kafkova, Lenka Calabkova, Vladimir Krystof, Petr Dolezel, Vladimir Divoky
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NR9508
MZ0
CEP Register
PubMed
19737069
DOI
10.1089/scd.2009.0065
Knihovny.cz E-resources
- MeSH
- Cell Line MeSH
- Cell Cycle drug effects MeSH
- HT29 Cells MeSH
- Time Factors MeSH
- Cyclin-Dependent Kinase 2 antagonists & inhibitors genetics metabolism MeSH
- Cyclin-Dependent Kinase 9 antagonists & inhibitors genetics metabolism MeSH
- Embryonic Stem Cells cytology drug effects metabolism MeSH
- G1 Phase drug effects MeSH
- Mice, Inbred Strains MeSH
- Inhibitory Concentration 50 MeSH
- Humans MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- CDC2 Protein Kinase antagonists & inhibitors genetics metabolism MeSH
- Flow Cytometry MeSH
- Purines pharmacology MeSH
- DNA Replication drug effects MeSH
- Cell Survival drug effects MeSH
- Blotting, Western MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Embryonic stem cells (ESCs) proliferate rapidly and have a unique cell-cycle structure with a very short G1 phase. Previous reports suggested that the rapid G1 phase progression of ESCs might be underpinned by high and precocious Cdk2 activity and that Cdk2 activity might be crucial for both cell-cycle regulation and cell-fate decisions in human ESCs. However, the actual role of Cdk2 in cell-cycle progression of mouse ESCs (mESCs) has not been elucidated. In this study, we investigated the effects of down-regulation of Cdk2 activity by olomoucine II in 2 mESC lines. Olomoucine II treatment significantly increased the G1 phase cell numbers, decreased the S phase cell numbers, and inhibited DNA replication in mESCs. In nocodazole-synchronized mESCs, we show that specific down-regulation of Cdk2 activity prolongs G1 phase progression. In addition, down-regulation of Cdk2 activity in mESCs established a somatic cell-like cell cycle and induced expression of differentiation markers. Our results suggest that high Cdk2 activity is essential for rapid G1 phase progression and establishment of ESC-specific cell-cycle structure in mESCs and support the hypothesis of a link between cell-cycle regulation and pluripotency maintenance in ESCs. This study reveals olomoucine II to be an effective tool for manipulation of the cell cycle and pluripotency in ESCs and very likely also for the manipulation of other stem cell types, including cancer stem cells.
Department of Biology Faculty of Medicine Palacky University Olomouc Czech Republic
Laboratory of Growth Regulators Faculty of Science Palacky University Olomouc Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025538
- 003
- CZ-PrNML
- 005
- 20140731180606.0
- 007
- ta
- 008
- 120816s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1089/scd.2009.0065 $2 doi
- 035 __
- $a (PubMed)19737069
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Koledová, Zuzana $7 jx20110603007 $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 245 10
- $a Cdk2 inhibition prolongs G1 phase progression in mouse embryonic stem cells / $c Zuzana Koledova, Leona Raskova Kafkova, Lenka Calabkova, Vladimir Krystof, Petr Dolezel, Vladimir Divoky
- 520 9_
- $a Embryonic stem cells (ESCs) proliferate rapidly and have a unique cell-cycle structure with a very short G1 phase. Previous reports suggested that the rapid G1 phase progression of ESCs might be underpinned by high and precocious Cdk2 activity and that Cdk2 activity might be crucial for both cell-cycle regulation and cell-fate decisions in human ESCs. However, the actual role of Cdk2 in cell-cycle progression of mouse ESCs (mESCs) has not been elucidated. In this study, we investigated the effects of down-regulation of Cdk2 activity by olomoucine II in 2 mESC lines. Olomoucine II treatment significantly increased the G1 phase cell numbers, decreased the S phase cell numbers, and inhibited DNA replication in mESCs. In nocodazole-synchronized mESCs, we show that specific down-regulation of Cdk2 activity prolongs G1 phase progression. In addition, down-regulation of Cdk2 activity in mESCs established a somatic cell-like cell cycle and induced expression of differentiation markers. Our results suggest that high Cdk2 activity is essential for rapid G1 phase progression and establishment of ESC-specific cell-cycle structure in mESCs and support the hypothesis of a link between cell-cycle regulation and pluripotency maintenance in ESCs. This study reveals olomoucine II to be an effective tool for manipulation of the cell cycle and pluripotency in ESCs and very likely also for the manipulation of other stem cell types, including cancer stem cells.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a proteinkinasa CDC2 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D016203
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a buněčné linie $7 D002460
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D051357
- 650 _2
- $a cyklin-dependentní kinasa 9 $x antagonisté a inhibitory $x genetika $x metabolismus $7 D042863
- 650 _2
- $a replikace DNA $x účinky léků $7 D004261
- 650 _2
- $a embryonální kmenové buňky $x cytologie $x účinky léků $x metabolismus $7 D053595
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a G1 fáze $x účinky léků $7 D016193
- 650 _2
- $a buňky HT-29 $7 D019073
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a inbrední kmeny myší $7 D008815
- 650 _2
- $a puriny $x farmakologie $7 D011687
- 650 _2
- $a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Rašková Kafková, Leona $7 xx0046461 $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Calábková, Lenka $7 xx0142626 $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Kryštof, Vladimír, $d 1973- $7 xx0097406 $u Laboratory of Growth Regulators, Faculty of Science, Palacky University, Olomouc, Czech Republic
- 700 1#
- $a Doležel, Petr. $7 xx0317513 $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Divoký, Vladimír $7 xx0018902 $u Department of Biology, Faculty of Medicine, Palacky University, Olomouc, Czech Republic
- 773 0_
- $w MED00162608 $t Stem cells and development $x 1557-8534 $g Roč. 19, č. 2 (2010), s. 181-194
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/19737069 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20140731180925 $b ABA008
- 999 __
- $a ok $b bmc $g 947580 $s 782884
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 19 $c 2 $d 181-194 $i 1557-8534 $m Stem cells and development $n Stem Cells Dev $x MED00162608
- GRA __
- $a NR9508 $p MZ0
- LZP __
- $a Pubmed-20120816/10/02